SCHEMBL875455

SCHEMBL875455

O=C(O)c1ccc2c(c1)CCCO2

nearest known ligand 0.67

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTNNB1 P35222 7/20 0.67
WNT3A P56704 7/20 0.67
ALDH1A1 P00352 3/20 0.58
PRKCI P41743 1/20 0.56
MAPK1 P28482 1/20 0.51
KDM4E B2RXH2 1/20 0.49
MAPT P10636 1/20 0.49
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
TDP1 Q9NUW8 1/20 0.47
ACHE P22303 1/20 0.46
CLK1 P49759 1/20 0.46
DYRK1A Q13627 1/20 0.46
DYRK1B Q9Y463 1/20 0.46
FABP4 P15090 1/20 0.45
TAS1R3 Q7RTX0 1/20 0.45
TAS1R1 Q7RTX1 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31262479 1.00 CTNNB1 (0.67) CTNNB1WNT3AALDH1A1PRKCIMAPK1
SCHEMBL24119388 0.95 CTNNB1 (0.61) CTNNB1WNT3AALDH1A1PRKCIMAPK1
SCHEMBL22025856 0.95 CTNNB1 (0.61) CTNNB1WNT3AALDH1A1PRKCIMAPK1
SCHEMBL20329998 0.95 CTNNB1 (0.61) CTNNB1WNT3AALDH1A1PRKCIMAPK1
SCHEMBL1395976 0.89 PRKCI (0.64) CTNNB1WNT3AALDH1A1PRKCIMAPK1
Hydrochloric Acid SCHEMBL4894045 0.88 PRKCI (0.62) CTNNB1WNT3AALDH1A1PRKCIMAPK1
SCHEMBL11239661 0.87 CTNNB1 (0.63) CTNNB1WNT3AALDH1A1PRKCINPC1
SCHEMBL30251781 0.86 ALDH1A1 (0.58) CTNNB1WNT3AALDH1A1MAPK1KDM4E
SCHEMBL5917930 0.86 ALDH1A1 (0.58) CTNNB1WNT3AALDH1A1MAPK1KDM4E
SCHEMBL1726294 0.85 CTNNB1 (0.61) CTNNB1WNT3APRKCIKDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107743483-B NADPH oxidase 4 inhibitors 埃科特莱茵药品有限公司 2022-01-28 CN claimed
US-20210395238-A1 NADPH OXIDASE 4 INHIBITORS ACTELTION PHARMACEUTICALS LTD (CH) 2021-12-23 US claimed
EP-3310767-B1 2,5-DISUBSTITUTED BENZOXAZOLE AND BENZOTHIAZOLE COMPOUNDS AS NADPH OXIDASE 4 INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2020-07-22 EP claimed
US-20200165235-A1 NADPH OXIDASE 4 INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2020-05-28 US claimed
US-10584118-B2 NADPH oxidase 4 inhibitors ACTELION PHARMACEUTICALS LTD (CH) 2020-03-10 US claimed
US-20180179194-A1 NADPH OXIDASE 4 INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2018-06-28 US claimed
EP-3310767-A1 NADPH OXIDASE 4 INHIBITORS Actelion Pharmaceuticals Ltd. (CH) 2018-04-25 EP claimed
CN-107743483-A NADPH oxidase 4 inhibitors 埃科特莱茵药品有限公司 2018-02-27 CN claimed
WO-2016207785-A1 NADPH OXIDASE 4 INHIBITORS ACTELION PHARMACEUTICALS LTD (CH) 2016-12-29 WO claimed
EP-2619178-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2013-07-31 EP claimed
WO-2012038081-A1 SUBSTITUTED BENZAMIDE COMPOUNDS Grünenthal GmbH (DE) 2012-03-29 WO claimed
US-12577243-B2 Monoacylglycerol lipase modulators JANSSEN PHARMACEUTICA NV (BE) 2026-03-17 US disclosed
EP-3856178-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-03-11 EP disclosed
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2025-11-13 US disclosed
CN-113164459-B Monoacylglycerol lipase modulators 詹森药业有限公司 2024-09-03 CN disclosed
WO-2003042210-A1 AZABICYCLIC-PHENYL-FUSED-HETEROCYCLIC COMPOUNDS AND THEIR USE AS ALPHA7 NACHR LIGANDS PHARMACIA & UPJOHN COMPANY (US) 2003-05-22 WO disclosed
CN-1214675-A Aryl or heteroaryl amides of tetrahydronaphthalene, chroman, thiochroman and 1,2,3,4-tetrahydroquinoline carboxylic acids having retinoid-like biological activity VISION PHARM LP (US) 1999-04-21 CN disclosed
CN-1084170-A Pyrazole derivatives IDEMITSU KOSAN CO (JP) 1994-03-23 CN disclosed
EP-0435681-A1 Chroman esters of phenols and benzoic acids having retinoid-like activity ALLERGAN, INC. (US) 1991-07-03 EP disclosed
US-5006550-A Skin disorder, arthritis, wound healing agents, dry eye syndrome ALLERGAN, INC. (US) 1991-04-09 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12577243-B2 Monoacylglycerol lipase modulators MGLL, LPL, FAAH CTNNB1 2402/4885WNT3A 1584/4885ALDH1A1 587/4885
US-10584118-B2 NADPH oxidase 4 inhibitors NOX4, NOX1, CYBB CTNNB1 2966/4885WNT3A 3987/4885ALDH1A1 176/4885
US-20200165235-A1 NADPH OXIDASE 4 INHIBITORS NOX4, NOX1, CYBB CTNNB1 2966/4885WNT3A 3987/4885ALDH1A1 176/4885
US-20250346585-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS C5, C1S, C9 CTNNB1 3731/4885WNT3A 4321/4885ALDH1A1 1707/4885
US-20180179194-A1 NADPH OXIDASE 4 INHIBITORS NOX4, NOX1, CYBB CTNNB1 2966/4885WNT3A 3987/4885ALDH1A1 176/4885
US-20210395238-A1 NADPH OXIDASE 4 INHIBITORS NOX4, NOX1, CYBB CTNNB1 2966/4885WNT3A 3987/4885ALDH1A1 176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.